Closed · W81XWH-19-ERP-RPA · CFDA 12.420 · Discretionary

DoD Epilepsy, Research Partnership Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
July 17, 2019
Close date
2
Expected awards

The verdict

DoD Epilepsy, Research Partnership Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 2 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
2
expected awards
12.420
CFDA program

Archived opportunity record

DoD Epilepsy, Research Partnership Award is closed (last close July 17, 2019). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed July 17, 2019

Posted May 16 Closes Jul 17

Est. Total Funding

$3,300,000

Expected Awards

2

Instrument

Grant

Description

The intent of the FY19 ERP RPA is to create an avenue for collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts. The FY19 ERP RPA offers two levels of funding. Funding Level I is intended to support preclinical or pre-validation research. Funding Level II is intended to support research requiring access to a patient cohort for a prospective study. Funding Level II applications that evaluate the feasibility of using combinations of measures (e.g., neuropsychological assessments, imaging, and genomics) are encouraged. Furthermore, Level II applications should describe how the association of TBI and subsequent PTE will be assessed or characterized to include a description of the nature of the TBIs in the cohort. The description of the TBI characterization should discuss how the TBIs will be studied using statistical methods as part of the statistical plan for Level II Applications. Applications should therefore describe how the anticipated outcome(s) can be attributable to the results of the proposed research (short-term gains), as well as consider the long-term scientific gains from the proposed research project. Applications should be impact-based. Note: Funding Level II is not intended to support animal research. The FY19 ERP RPA is open to eligible applicants whose named Principal Investigators (PIs) are at or above the level of Assistant Professor (or equivalent) from any field or discipline. The application should demonstrate the study team’s experience in both TBI and epilepsy research. The FY19 ERP RPA requires that a minimum of two investigators (i.e., partners) jointly design a single research project. It should be clear that each partner had equal intellectual input into the design of the research project. Any partner may submit as the PI; the other partner(s) will be designated as the Co-PI(s). Multi-institutional research is encouraged but not required. The success of the project must be supported by the unique skills and contributions of each partner. The proposed studies must demonstrate how they will accelerate research that addresses the ERP’s mission (see Section II.A, Program Description) toward clinical applications. All applications must include a Collaboration Statement (Attachment 10). The proposed study must include clearly stated plans for interactions between/among the partners. The plans must include communication, decision-making, allocation of resources, coordination of research progress and results, and sharing of data among all investigators and organizations participating in the project. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.For Both Funding Levels: Preliminary data to support the feasibility of the research hypothesis (or hypotheses) and research approaches are required. Preliminary data may be derived from a laboratory discovery, clinical observation, or population-based studies. The proposed research must be relevant to active duty Service members, Veterans, military beneficiaries, and the American public. For Funding Level I: The anticipated total costs budgeted for the entire period of performance for a Funding Level I FY19 ERP RPA will not exceed $1,300,000. The maximum period of performance is 3 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. For Funding Level II: The anticipated total costs budgeted for the entire period of performance for a Funding Level II FY19 ERP RPA will not exceed $2,000,000. The maximum period of performance is 4 years. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. The requested budget level should be appropriate for the scope of research proposed. FY19 ERP RPA Focus Areas: The Focus Areas below are specific to the FY19 ERP RPA and should be carefully considered as part of the application process. • Markers and Mechanisms • Epidemiology • Longitudinal Studies An application that proposes research outside of these FY19 ERP RPA Focus Areas is acceptable, as long as the applicant provides a strong rationale. These should be carefully considered as part of the application process. The CDMRP expects to allot approximately $1.3M to fund approximately one RPA Funding Level I application and approximately $2.0M to fund approximately one RPA Funding Level II application. Funding of applications received is contingent upon the availability of Federal funds for this program as well as the number of applications received, the quality and merit of the applications as evaluated by scientific and programmatic review, and the requirements of the Government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY19 funding opportunity will be funded with FY19 funds, which will expire for use on September 30, 2025. Awards will be made no later than September 30, 2020. For additional information refer to Section II.F.1, Federal Award Notices.

Catch-all / unrestricted eligibility mark · W81XWH-19-ERP-RPA

Grants.gov marks DoD Epilepsy, Research Partnership Award with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

What to do next

DoD Epilepsy, Research Partnership Award is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants